text stringlengths 31 63k | label stringclasses 6 values |
|---|---|
Through an assignment and option agreement with Connetics in 1998, we paid Connetics $5.7 million to acquire rights to Actimmune and we remain obligated to pay to Connetics a royalty of 0.25% of our net United States sales for Actimmune until our net United States sales cumulatively surpass $1.0 billion. Above $1.0 billion, we are obligated to pay a royalty of 0.5% of our net United States sales of Actimmune. Through a separate purchase agreement, we paid Connetics $0.4 million to acquire rights related to the use of Actimmune to treat scleroderma and are obligated to pay Connetics a royalty of 4.0% on our net revenue from sales of Actimmune for the treatment of scleroderma. We made royalty payments of approximately $1.9 million in the aggregate through December 31, 2011. There are no milestone payments pursuant to this agreement. | cmp |
In February 2017, the Company entered into a grant agreement with the Gates Foundation pursuant to which the Company has no payment obligations under the Adimab Option Agreement with respect to sales of products based on licensed RSV antibodies to the extent they are sold at cost in developing countries. However, if such products are sold in developing countries for an amount that exceeds cost, then the amount of such excess will be subject to the royalty payment obligations described in the preceding paragraph. | cmp |
Our direct research and development expenses are tracked on a program-by-program basis for our product candidates and consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and central laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses by program also include fees incurred under license or option agreements. We do not allocate employee costs or facility expenses, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track their costs by program. | cmp |
Stanford Exclusive License Agreement and Option Agreement In December 2020, we entered into an exclusive license agreement (the License Agreement), with The Board of Trustees of the Leland Stanford Junior University (Stanford), pursuant to which Stanford granted us a worldwide license to specified technology and patent rights to develop, manufacture and commercialize human prophylactic and therapeutic products. Other than with respect to specified, broadly applicable assays and procedures and subject to retained rights by Stanford, the license is exclusive with respect to human prophylactic and therapeutic products for the treatment of SCD, XSCID and beta thalassemia. The license is non-exclusive with respect to those broadly applicable assays and procedures and with respect to all human prophylactic and therapeutic products other than for the treatment of SCD, XSCID and beta thalassemia. | cmp |
OPTION AGREEMENT made this _____ day of ________, ____, between Cadapult Graphic Systems, Inc., a Delaware corporation (the "Company"), and ___________________, a management-level employee of the Company or one or more of its subsidiaries (the "Employee"). | cmp |
IN WITNESS WHEREOF the Company has caused this Option Agreement to be duly executed by its officers thereunto duly authorized, and the Employee has hereunto set his/her hand and seal, all on the day and year first above written. | cmp |
OPTION AGREEMENT made this _____day of __________, _____, between Cadapult Graphic Systems, Inc., a Delaware corporation (the "Company"), and ________________, an employee of the Company or one or more of its subsidiaries (the "Employee"). | cmp |
Through an assignment and option agreement with Connetics, we paid Connetics $5.7 million to acquire rights to Actimmune and are obligated to pay to Connetics a royalty of 0.25% of our net United States sales for Actimmune until our net United States sales cumulatively surpass $1.0 billion. Above $1.0 billion, we are obligated to pay a royalty of 0.5% of our net United States sales of Actimmune. Through a separate purchase agreement, we paid Connetics $0.4 million to acquire rights related to scleroderma and are obligated to pay Connetics a royalty of 4.0% on our net revenue from sales of Actimmune for the treatment of scleroderma. We made royalty payments of approximately $1.9 million in the aggregate through December 31, 2011. There are no milestone payments pursuant to this agreement. | cmp |
(e) Ownership of the Option. Paxson is the lawful owner of the Option free and clear of all liens, security interests, claims or encumbrances of any nature whatsoever and has the right under the Option Agreement to transfer the Option of Buyer. Pursuant to Section 3 hereof, Paxson will give to Sellers the notices required by the Option Agreement to effectuate this assignment. The Option Agreement is in full force and effect. | cmp |
A. Paxson, Whitehead Media, Inc. ("Whitehead"), Whitehead Broadcasting of Georgia, Inc. ("Whitehead-Broadcasting") and Whitehead Media of Georgia, Inc. ("Whitehead-Georgia") ("Whitehead-Broadcasting and Whitehead-Ohio are collectively referred to herein as the "Sellers" and individually as a "Seller") are parties to an Option Agreement dated December 29, 1995 as amended on December 31, 1996, and further amended on March 26, 1997 (as amended, the "Option Agreement"), pursuant to which Sellers have granted to Paxson an exclusive and irrevocable option (the "Option") to purchase the assets, real personal and mixed, tangible and intangible, owned and held by Sellers that are used or useful in the conduct of the business and operations of Television Station WNGM(TV), Channel 34, Athens, Georgia (the "Station") (such assets are referred to herein as the "Station Assets"). | cmp |
(e) Ownership of the Option. Paxson is the lawful owner of the Option free and clear of all liens, security interests, claims or encumbrances of any nature whatsoever and has the right under the Option Agreement to transfer the Option to Buyer. Pursuant to Section 3 hereof, Paxson will give to Sellers all notices required by the Option Agreement to effectuate this assignment. The Option Agreement is in full force and effect. | cmp |
The Company is obligated to use diligent efforts to develop the AR Mutant Program according to agreed upon development plans, timelines and budgets. The Company is further obligated as it relates to the AR Mutant Program to use commercially reasonable efforts to develop, obtain marketing approval for, and commercialize licensed products. Until the expiration or earlier termination of the development term of the AR Mutant Program, under the License and Option Agreement, subject to specified exceptions, the Company has agreed not to research, develop or commercialize any compounds or products related to the AR Mutant Program, other than pursuant to the collaboration with Janssen. | cmp |
A. Seller, Roberts Broadcasting Company of North Carolina ("Roberts"), and Roberts Broadcasting Company of Raleigh-Durham, L.P. (the "Company") are parties to an Option Agreement dated October 31, 1995, as amended by that Amendment to Option Agreement dated as of January 19, 1996 (as amended, the "Option Agreement"), pursuant to which Roberts granted to Seller an exclusive and irrevocable option (the "Option") to purchase all of the limited partnership interests held by Roberts in the Company. | cmp |
SECOND AMENDMENT TO STOCK PURCHASE AND OPTION AGREEMENT | cmp |
A. Seller is a party to an Option Agreement dated as of December 29, 1995 with Whitehead Media, Inc. ("Whitehead") and Whitehead Media of Florida, Inc. ("Whitehead-Florida"), as amended by letter dated June 18, 1996 from Paxson Communications Corporation to Whitehead, Whitehead-Florida and certain other affiliates thereof and by First Amendment to Option Agreement dated as of December 31, 1996 with Whitehead, Whitehead-Florida and Whitehead Broadcasting of Florida, Inc. ("Whitehead-Broadcasting") (such Option Agreement, as amended, shall be referred to herein as the "Option Agreement"), pursuant to which Whitehead-Florida and Whitehead-Broadcasting (collectively, the "Whitehead Companies") have granted to Seller an exclusive and irrevocable option (the "Option") to acquire substantially all of the assets of Television Station WTVX-TV, Ft. Pierce, Florida (the "Station"). | cmp |
A. Seller and Buyer are parties to an Option Agreement dated as of July 9, 1996 (the "Option Agreement"), pursuant to which Seller granted to Buyer an option (the "Option") to acquire from Seller substantially all of the assets used or useful in the business or operations of Television Station WHKE-TV, Kenosha, Wisconsin (the "Station"). | cmp |
On December 21, 2019, we entered into a license, collaboration, and option agreement (the Collaboration Agreement) with F. Hoffman-La Roche Ltd (Roche) pursuant to which we granted Roche an exclusive license under certain of our intellectual property rights to develop, manufacture, and commercialize SRP-9001 in all countries outside of the U.S. We retained all rights to SRP-9001 in the U.S. The transaction closed on February 4, 2020. We have entered into Amendments 1 through 10 to the Collaboration Agreement on: October 23, 2020, October 28, 2020, February 4, 2021, June 23, 2021, August 31, 2021, November 30, 2021, January 5, 2022, January 28, 2022, April 4, 2022, and July 26, 2022, respectively. | cmp |
Provided, however, that the provisions of this clause shall not (a) prevent the granting to any key employee holding an unexpired option under this plan, of an additional option(s) under this plan; (b) withdraw the administration of this Plan from the committee; (c) permit any member of the committee to be eligible to receive or hold an option under the Plan; and (d) alter any outstanding option agreement to the detriment of the key employee holding the option without the consent of such employee. | cmp |
A. Paxson, Whitehead Media, Inc. ("Whitehead"), Whitehead Broadcasting of Ohio, Inc. ("Whitehead-Broadcasting") and Whitehead Media of Ohio, Inc. ("Whitehead-Ohio") (Whitehead-Broadcasting and Whitehead-Ohio are collectively referred to herein as the "Sellers" and individually as a "Seller") are parties to an Option Agreement (the "Option Agreement"), dated December 29, 1995 as amended on December 31, 1996 and as further amended on March 21, 1997 (as amended, the "Option Agreement"), pursuant to which Sellers have granted to Paxson an exclusive and irrevocable option (the "Option") to purchase the assets, real, personal and mixed, tangible and intangible, owned and held by Sellers that are used or useful in the conduct of the business and operations of Television Station WOAC (TV), Channel 67, Canton, Ohio (the "Station") (such assets are referred to herein as the "Station Assets"). | cmp |
(11) "OPTION AGREEMENT" means an agreement between the Company and a Participant executed and delivered pursuant to the Plan. | cmp |
Notwithstanding the foregoing, this Section shall not release Ekco from the obligations expressly set forth in this Agreement, any ongoing indemnification obligation (including any right to advancement of expenses) set forth in the By Laws of the Company or any of its subsidiaries, or with respect to the Indemnification Agreement dated as of July 30, 1986 between you and the Company (the "Indemnification Agreement") or as a matter of law, Remaining Option Agreements, or distributions not yet made to you under the terms of the ESOP, 401(k) or the ESPP. Without limiting the generality of the foregoing, the Company will indemnify, defend and hold you harmless against claims brought against you for recovery of amounts paid or payable to you under this Agreement, provided that such indemnification and defense shall be subject to the same limitations on indemnification as are applicable to indemnification of officers and directors under the Delaware General Corporation Law. | cmp |
In the normal course of business, we post letters of credit and surety bonds pursuant to certain performance-related obligations, as security for certain land option agreements, and under various insurance programs. The majority of these letters of credit and surety bonds are in support of our land development and construction obligations to various municipalities, other government agencies, and utility companies related to the construction of roads, sewers, and other infrastructure. We had outstanding letters of credit and surety bonds totaling $219.1 million and $1.1 billion, respectively, at December 31, 2016, and $191.3 million and $1.0 billion, respectively, at December 31, 2015. In the event any such letter of credit or surety bonds is drawn, we would be obligated to reimburse the issuer of the letter of credit or surety bond. We do not believe that a material amount, if any, of the letters of credit or surety bonds will be drawn. Our surety bonds generally do not have stated expiration dates; rather we are released from the surety bonds as the underlying contractual performance is completed. Because significant construction and development work has been performed related to the applicable projects but has not yet received final acceptance by the respective counterparties, the aggregate amount of surety bonds outstanding is in excess of the projected cost of the remaining work to be performed. | cmp |
Of our controlled lots, 99,279 and 95,919 were owned and 43,979 and 42,160 were under land option agreements at December 31, 2016 and 2015, respectively. While competition for well-positioned land is robust, we continue to pursue strategic land positions that drive appropriate returns on invested capital. The remaining purchase price under our land option agreements totaled $2.1 billion at December 31, 2016. These land option agreements generally may be canceled at our discretion and in certain cases extend over several years. Our maximum exposure related to these land option agreements is generally limited to our deposits and pre-acquisition costs, which totaled $195.4 million, of which $9.8 million is refundable, at December 31, 2016. | cmp |
Another source of liquidity includes our ability to use letters of credit and surety bonds pursuant to certain performance-related obligations and as security for certain land option agreements and under various insurance programs. The majority of these letters of credit and surety bonds are in support of our land development and construction obligations to various municipalities, other government agencies, and utility companies related to the construction of roads, sewers, and other infrastructure. At December 31, 2016, we had outstanding letters of credit and surety bonds totaling $219.1 million and $1.1 billion, respectively. These letters of credit are issued via our unsecured revolving credit facility, which contains certain financial covenants and other limitations. If we are unable to obtain letters of credit or surety bonds when required, or the conditions imposed by issuers increase significantly, our financial condition and results of operations could be adversely affected. | cmp |
(q) "Notice of Grant" means a written or electronic notice evidencing certain terms and conditions of an individual Option or Stock Purchase Right grant. The Notice of Grant is part of, and subject to the terms of, the Option Agreement. | cmp |
On April 1, 2014, Generation and EDF entered into various agreements including a Nuclear Operating Services Agreement, an amended LLC Operating Agreement, an Employee Matters Agreement, and a Put Option Agreement, among others. Under the amended Operating Agreement, CENG made a $400 million special distribution to EDF | cmp |
**Anbar License Agreement.** In March 1997, we entered into an option agreement with Michael Anbar, Ph.D., Professor in the Department of Physiology and Biophysics, School of Medicine, and Chairman of Biomedical Sciences, at the State University of New York at Buffalo (now retired), pursuant to which we acquired the exclusive worldwide right to commercialize the technology relating to a patent owned by Dr. Anbar, subject to specified research funding requirements being met. The Anbar patent is entitled "Detection of cancerous lesions by their effect on the periodic modulation of perfusion on the surrounding tissue." This patent describes the disease related physiological processes, which occur in the presence of cancerous tumors, as well as the method by which Bio Scan IR analyzes radiation emitted by tissue surrounding cancerous tumors. We are required to pay Dr. Anbar a royalty of $300 for each commercial Bio Scan IR system installed at a client site. The Anbar license does not expire other than as a result of a breach of the license by us. The Anbar patent expires in January 2015\. | cmp |
On July 20, 2017, our wholly owned subsidiary, Aptevo Research and Development LLC, or Aptevo R&D, entered into a collaboration and option agreement (Collaboration Agreement) with Alligator Bioscience AB, or Alligator, pursuant to which Aptevo R&D and Alligator will collaboratively develop ALG.APV-527, Under this collaboration agreement, Alligator also granted to Aptevo R&D a time-limited option to enter into a second agreement with Alligator for the joint development of a separate bispecific antibody candidate simultaneously targeting 4-1 BB (CD 137) and 5 T 4. | cmp |
On July 20, 2017, our wholly owned subsidiary Aptevo Research and Development LLC (Aptevo R&D), entered into a collaboration and option agreement (Collaboration Agreement) with Alligator Bioscience AB, (Alligator), pursuant to which Aptevo and Alligator will collaboratively develop ALG.APV-527, a lead bispecific antibody candidate simultaneously targeting 4-1 BB (CD 137), a member of the TNFR superfamily of a costimulatory receptor found on activated T-cells, and 5 T 4 a tumor antigen widely overexpressed in a number of different types of cancer. This product candidate is built on our novel ADAPTIR platform, which is designed to expand on the utility and effectiveness of therapeutic antibodies. Under this Collaboration Agreement, Alligator also granted to Aptevo a time-limited option to enter into a second agreement with Alligator for the joint development of a separate bispecific antibody candidate simultaneously targeting 4-1 BB (CD 137) and 5 T 4 a tumor antigen that Aptevo R&D and Alligator will collaboratively select. | cmp |
(b) The Company shall pay the Executive's reasonable fees and costs incurred in connection with the preparation and negotiation of this Agreement, the Option Plan, the Option Agreement that pertains to Options granted under the Option Plan and the Management Stockholders' Agreement. | cmp |
(p) "OPTION AGREEMENTS" shall mean the written agreements between the Company and the Executive pursuant to which the Executive holds or is granted options to purchase Common Stock, including, without limitation, agreements evidencing options granted under the Option Plan and agreements governing the terms of "Roll-Over Options" (as defined in the Management Stockholders' Agreement): | cmp |
Options granted under the Plan shall not be affected by any change of employment or other service within or among the Company and any subsidiaries, so long as the optionee continues to be an employee or consultant of the Company or any subsidiary, provided, however, if an optionee's employment by either the Company or a subsidiary should cease (other than to become an employee of a subsidiary or the Company), such termination shall affect the optionee's rights under any Option granted to such optionee in accordance with the terms of the Plan and the pertinent Option agreement. | cmp |
10.2 Indemnification by NESI. NESI shall defend, indemnify and hold harmless USL and its Affiliates and their employees, officers, owners, directors, agents and subcontractors, from and against any and all liabilities, penalties, fines, forfeitures, demands, claims, causes of action, suits, judgments and costs and expenses incidental thereto, including reasonable attorneys' fees, which any or all of them may hereafter suffer, incur, be responsible for or pay out with respect to claims by third parties for personal injuries, property damage or other loss to the extent directly or indirectly caused by, or arising from or in connection with (i) the negligence, gross negligence or willful act or omission of NESI, any of its employees, officers, owners, directors, agents or subcontractors or any third-party generator acting at NESI's direction in the performance of this Option Agreement, (ii) the violation of any environmental rule, law or regulation by NESI, any of its employees, officers, owners, directors, agents or subcontractors or any third-party generator acting at NESI's direction; (iii) material delivered to any of the Landfarms by NESI or any third-party generator acting at NESI's direction which is not in accordance with the terms of this Option Agreement or otherwise not permitted to be disposed at such Landfarm; or (iv) the breach of, misrepresentation in, untruth in or inaccuracy in any representation, warranty or covenant of NESI set forth in this Option Agreement. | cmp |
10.1 Indemnification by USL. USL shall defend, indemnify and hold harmless NESI and its Affiliates and their employees, officers, owners, directors and agents, from and against any and all liabilities, penalties, fines, forfeitures, demands, claims, causes of action, suits, judgments and costs and expenses incidental thereto, including reasonable attorneys' fees, which any or all of them may hereafter suffer, incur, be responsible for or pay out as a result of personal injuries, property damage, or contamination of or adverse effects on the environment, to the extent directly or indirectly caused by, or arising from or in connection with (i) the negligence, gross negligence or willful act or omission or willful misconduct of USL or any of its employees, officers, owners, directors, agents or subcontractors in the performance of this Option Agreement; (ii) the violation of any environmental rule, law or regulation by USL or any of its employees, officers, owners, directors, agents or subcontractors; (iii) operations of the Landfarms, including, without limitation, the receipt and disposal of waste delivered to the Landfarms by NESI and others; or (iv) the breach of, misrepresentation in, untruth in or inaccuracy in any representation, warranty or covenant of USL set forth in this Option Agreement. | cmp |
The Company is required to pay to the BLM on or before September 1 st of each year, a fee in the amount of $155 per mineral claim held by the Company. The total amount paid in August 2015, was $50,840 for 328 claims held by the Company at that date. The BLM fee for the 18 NL Project claims held by the Company was paid by IMMI pursuant to the IMMI Option Agreement described above. | cmp |
A. Scripps and Licensee have entered into a Research Funding and Option Agreement effective as of November 14, 1997 (the "Research Agreement"), pursuant to which Licensee agreed to fund certain research conducted in Dr. Nora Sarvetnick's laboratory at Scripps (the "Research Program"). | cmp |
The Company and CLOG II LLC (the "Optionee") entered into an Option Agreement, dated November 29, 2000, (the "Option Agreement"). Pursuant to the Option Agreement, the Company has granted an option to the Optionee to purchase convertible debentures of the Company having an aggregate principal amount of up to $2,040,000. Per the Option Agreement, the option shall terminate on November 29, 2002. | cmp |
(p) "Notice of Grant" means a written or electronic notice --------------- evidencing certain terms and conditions of an individual Option or Stock Purchase Right grant. The Notice of Grant is part of the Option Agreement. | cmp |
(OO) Form of Argosy Energy Incorporated Non- Incentive Stock
Option Agreement for non- employees, incorporated by
reference to Exhibit 10(DD) to Registrant's Form 10-K for
the fiscal year ended December 31, 1988. * | cmp |
10.3 Amendment to Lake Owen Option Agreement, dated June 12, 2000, between General Minerals Corporation and the Company; and Warrant Agreement, dated June 12, 2000, between the Company and General Minerals Corporation. (5) 10.4 Amendment to Stock Purchase Agreement, dated as of June 27, 2000, by and between Electrum LLC and the Company; and Warrant Agreement, dated June 9, 2000, by and between the Company and Tigris Financial Group Ltd. (5) | cmp |
The Company also intends to pursue limited new property development opportunities that are otherwise consistent with the Company's overall business strategy. During 2000, the Company committed to acquire in early 2002 a 99,500 square foot office building in suburban Milwaukee currently under construction that the Company caused to be built. In 1999, the Company completed the acquisition of a newly developed 96,700 square foot property in suburban Milwaukee that the Company had caused to be built. In January 2001, the Company completed an option agreement under which the Company may elect to purchase approximately 23 acres of land located in Englewood, Colorado over the next two years upon which up to 400,000 square feet of office space could be constructed. The Company also intends to enhance its leasing flexibility by offering build-to-suit development options to current and prospective tenants who require space that is otherwise unavailable in a particular market. In addition, the Company will continue to pursue the redevelopment of older properties in attractive locations. | cmp |
In the normal course of business, we post letters of credit and surety bonds pursuant to certain performance-related obligations, as security for certain land option agreements, and under various insurance programs. The majority of these letters of credit and surety bonds are in support of our land development and construction obligations to various municipalities, other government agencies, and utility companies related to the construction of roads, sewers, and other infrastructure. We had outstanding letters of credit and surety bonds totaling $298.8 million and $1.8 billion, respectively, at December 31, 2021, and $249.7 million and $1.5 billion, respectively, at December 31, 2020. In the event any such letter of credit or surety bonds is drawn, we would be obligated to reimburse the issuer of the letter of credit or surety bond. We do not believe that a material amount, if any, of the letters of credit or surety bonds will be drawn. Our surety bonds generally do not have stated expiration dates; rather, we are released from the surety bonds as the underlying contractual performance is completed. Because significant construction and development work has been performed related to the applicable projects but has not yet received final acceptance by the respective counterparties, the aggregate amount of surety bonds outstanding is in excess of the projected cost of the remaining work to be performed. | cmp |
(NN) Form of Argosy Energy Incorporated Non- Incentive Stock
Option Agreement for employees, incorporated by reference
to Exhibit 10(CC) to Registrant's Form 10-K for the
fiscal year ended December 31, 1988. * | cmp |
Therefore, we were deemed to be in default of the Option Agreement. In accordance with the terms and provisions of the Option Agreement, and in the event of a default, we were to automatically forfeit and transfer back to Westrock the Leases. Legal opinions were received from Westrocks counsel and Mainland Resources counsel, both of which advised that we would have no legal grounds to retain the Leases. We engaged our own legal counsel to provide advice on this matter. Our legal counsel concurred with the two other legal opinions. On December 12, 2011, we entered into a transfer of oil, gas and mineral leases with Westrock (the Transfer of Leases), pursuant to which we transferred, delivered and assigned to Westrock all of our interests in and to those certain Leases. | cmp |
10.15 Confidentiality. (a) Each of the Administrative Agent and each Lender agrees to keep confidential, and to not publish, disclose or otherwise divulge to any Person, all non-public materials, reports, certificates, documents and other information provided to it by any Group Member pursuant to this Agreement that is designated by such Group Member as confidential (the "Information"), and to cause its respective officers, directors, employees, agents and representatives to keep confidential (including for purposes of Regulation FD), and to not publish, disclose or otherwise divulge to any Person, the Information, except that the Administrative Agent and each Lender shall be permitted to disclose the Information (i) to such of its, or any of its Affiliates', officers, directors, employees, agents and representatives as need to know such Information in connection with the servicing and protection of its interests in respect of its Loans and Commitments, the Loan Documents and the transactions contemplated hereby and thereby; (ii) to the extent required by applicable laws and regulations or by any subpoena or similar legal process, or requested by any regulatory authority or Governmental Authority having jurisdiction over it; provided, that, if, and to the extent, permitted by law and if reasonably practicable, such Administrative Agent or Lender first provides to Holdings and the Borrowers notice of such subpoena or request and gives Holdings and the Borrowers an opportunity to contest such subpoena or request; (iii) to the extent such Information (A) becomes publicly available other than as a result of a breach of this Agreement, (B) becomes available to the Administrative Agent or such Lender, as applicable, on a non- confidential basis from a source other than any Group Member or (C) was available to the Administrative Agent or such Lender, as applicable, on a non-confidential basis prior to its disclosure to the Administrative Agent or such Lender, as applicable, by a Group Member; (iv) to any direct or indirect contractual counterparty in swap agreements or such contractual counterparty's professional advisor (so long as such contractual counterparty or professional advisor to such contractual counterparty agrees to be bound by the provisions of this Section 10.15) or (v) to the extent the applicable Group Member shall have consented to such disclosure in writing. | cmp |
10.7 Form of Option Agreement for the Grant of Options to Acquire the Common Stock of Toyota Motor Corporation* Filed Herewith - ---------------- (23) Incorporated herein by reference to Exhibit 10.15 filed with the Company's Report on Form 10-Q for the quarter ended September 30, 2002, Commission File No. 1-9961. (10) Incorporated herein by reference to Exhibit 10.1 filed with the Company's Report on Form 10-Q for the quarter ended December 31, 1995, Commission File No. 1-9961. (11) Incorporated herein by reference to Exhibit 10.2 filed with the Company's Report on Form 10-Q for the quarter ended December 31, 1995, Commission File No. 1-9961. *- Management contract or compensatory plan or arrangement required to be filed as an exhibit pursuant to applicable rules of the Securities and Exchange Commission. (39) Incorporated herein by reference to Exhibit 10.8 filed with the Company's Report on Form 10-K for the year ended March 31, 2002, Commission File No. 1-9961. | cmp |
4.12 Regulatory Matters. American Investment Services, Inc. (#21111) ------------------ and AISCO Trading, Inc. (#40901) are registered as broker-dealers pursuant to Section 15 of the Securities Exchange Act of 1934, as amended, and a member in good standing with the National Association of Securities Dealers, Inc. ("NASD"). AISCO Futures, Inc. is registered under the Commodity Futures Trading Act. AISCO Agencies, Inc. is registered as an insurance broker under various state statutes. The AISCO Disclosure Schedule lists all employees, consultants and agents of AISCO and the AISCO Subsidiaries that are licensed with the NASD and any state securities commission, including a description of the licenses held (collectively referred to as the "Licensed Persons"). The AISCO Disclosure Schedule describes all customer complaints and regulatory inquiries of AISCO, any AISCO Subsidiary and any of the Licensed Persons over the last two years. | cmp |
(t) "Option Agreements" shall mean the written agreements between the Company and the Executive pursuant to which the Executive holds or is granted options to purchase Common Stock, including, without limitation, agreements evidencing options granted under the Option Plan and agreements governing the terms of "Roll-Over Options" (as defined in the Management Stockholders' Agreement). | cmp |
15. PLAN CONTROLLING. This Option Agreement is executed pursuant to the provisions of the Plan and is subject to all of the provisions of the Plan which shall be controlling. | cmp |
The terms of this Agreement, together with the Management Stockholders' Agreement, the Option Plan and the Option Agreements, are intended by the parties to be the final expression of their agreement with respect to the employment of the Executive by the Company and may not be contradicted by evidence of any prior or contemporaneous agreement. The parties further intend that this Agreement, and the aforementioned contemporaneous documents, shall constitute the complete and exclusive statement of its terms and that no extrinsic evidence whatsoever may be introduced in any judicial, administrative, or other legal proceeding to vary the terms of this Agreement. Notwithstanding any of the foregoing to the contrary, in the event of a conflict between the terms of this Agreement and the Management Stockholders' Agreement, the terms of this Agreement shall govern. | cmp |
Under the terms of the letter of intent our company and Ms. Diaz would be required to enter into an option agreement on or before August 31, 2011. Pursuant to the option agreement our company would be required advance $10,000 to Ms. Diaz to cover reimbursement on the 39 Sodaville Claims which would be deducted from the required payment of $210,000 to Ms. Diaz upon execution of the option agreement. | cmp |
(a) Except as to Options granted pursuant to the Voluntary Management Stock Accumulation Program, the right to purchase Stock pursuant to an Option Agreement shall become vested in accordance with the following schedule: | cmp |
13.2 No Set-Off Rights. The parties hereby agree that neither party shall have any right to set-off or apply against any sums due under this Option Agreement any sums due or amounts otherwise owing pursuant to any other provision of this Option Agreement or any other agreement or arrangement between the parties. | cmp |
13.1 Status of the Parties. Each party hereto is and shall perform this Option Agreement as an independent contractor, and as such, shall have and maintain complete control over all of its employees, agents, and operations. Except as expressly otherwise provided in this Option Agreement, neither party nor anyone employed by it shall be, represent, act, purport to act or be deemed to be the agent, representative, employee or servant of the other party. | cmp |
6.1 Compliance with Operating Procedures. NESI and its Affiliates shall comply in all material respects with and abide by, and shall require their employees, servants, agents, representatives, contractors, subcontractors, haulers and transporters to comply in all material respects with and abide by, all applicable federal, state and local laws, ordinances, permits, regulations, directives, codes, standards and requirements relating to the subject matter of this Option Agreement or the performance of services hereunder, as well as all of USL's rules, regulations, procedures and guidelines, written or oral, as the same may be reasonably adopted and modified from time to time, including, without limitation, all safety and/or security regulations, practices and procedures, and all procedures reasonably adopted by USL in compliance with its permits or utilized by USL in the inspection, sampling and testing of material delivered to any Landfarm for disposal. | cmp |
Our Technology Portfolio is comprised of two proprietary platforms. All the patents are owned by Yeda, and we license them exclusively on a worldwide basis. The two platforms are: Anti Third Party Veto-Cell and Organsource. Each platform already has been granted patents and has further patents pending. The total relevant patent portfolio consists of 6 inventions, 17 patent families, 11 granted patents, one allowed patent, and a further 78 pending patents. The patents for the Veto Cell and Megadose Drug Combination and T-regulatory cells are already licensed. Those for the organ platform are covered under an exclusive option agreement whereby Cell Source has until December 31 st, 2015 to decide whether it wants to license those patents. We currently license all of the patents related to our Anti Third Party Veto-Cell technology from Yeda. The key terms of the agreement pursuant to which we license all of Yedas patents related to our technology is set forth in the section entitled Intellectual Property herein. The license period (per product, per country) is for the full life of the patents, and expires at the later of the patent expiration date in that country or 15 years after the date that the FDA or local equivalent regulatory authority in each country approves that particular product for sale in that country. As long as Cell Source pays either a nominal license fee of $50,000 per year (total for use of all the products) or pays royalties on product sales on at least one product as per the license agreement, the license will remain in effect continuously and expire only with the expiration of the patent or 15 years after regulatory approval (later of the two) per product per country as described above. Cell Source voluntarily sponsors Research at the Weizmann Institute for the sake of developing its products and treatments from initial invention through to finalization of human treatment protocols. Cell Source has recently extended the initial research period, which terminated in October of 2014, for a further four years through October 2018. | cmp |
Also under the Yeda License Agreement, the Company agreed to fund Yedas research until October 3, 2018, with an aggregate annual payment of US $800,000 paid in quarterly US $200,000 installments. However, in the event that the Company and Yeda execute a new research and license agreement, then the Company will annually fund research in the amount of US $900,000 until Oct. 3, 2018. Such a new research and license agreement must be in accordance with the Evaluation and Exclusive Option Agreement by and between the Company and Yeda, dated Oct. 3, 2011, as amended on April 1, 2014 and June 22, 2014 (the E&O Agreement). Among other things, the E&O Agreement grants Cell Source an option to negotiate a commercial license in the field of organ transplantation with Yeda (the Option to Negotiate). The Option to Negotiate requires an initiation fee of $200,000 payable to Yeda, which may be paid on the later of (i) the date on which the Option to Negotiate is granted and (ii) the date on which the Company receives an aggregate investment amount of at least US $10,000,000. Pursuant to an amendment to the license agreement, the Option to Negotiate expires on December 31, 2015. | cmp |
In December 2018, the Company entered into an evaluation, option and license agreement, or the Novartis Option Agreement, with Novartis International Pharmaceutical Limited, or Novartis, pursuant to which Novartis agreed to conduct certain studies to evaluate AL 102 in combination with its B-cell maturation antigen, or BCMA, therapies in multiple myeloma, and the Company agreed to supply AL 102 for such studies. All supply and development costs associated with such evaluation studies are fully borne by Novartis. | cmp |
Billiton hereby subscribes for and agrees to purchase the Units and the Company hereby agrees to issue and sell the same to Billiton for the Unit Proceeds. The Company shall issue such Units to Billiton and simultaneously therewith grant to Billiton UK Resources B.V., an Affiliate of Billiton, the First Property Option pursuant to the Option Agreement on the Closing Date against receipt of the Unit Proceeds. | cmp |
(b) A Member may transfer all or any portion of its or his LLC Interest (i) to any one or more Permitted Transferees or Related Entities who agree to be bound by the terms and conditions of this Agreement, or (ii) upon obtaining the prior approval of the Board in accordance with Section 5.11 hereof, to any other Person who agrees to be bound by the terms and conditions of this Agreement; provided, however, that notwithstanding anything contained in this Agreement to the contrary, the transferring Member shall retain the right to vote with respect to LLC Interests Transferred unless (A) the transferee is WTI, WTC, Wilmington or an officer of the LLC, (B) the Transfer is pursuant to an Option Agreement, or (C) the transferee is approved by the Board as a Voting Member. | cmp |
4.3 Invoice for Additional Services: USL shall invoice NESI on a monthly basis for fees or expenses incurred from any services performed pursuant to Section 4.1 or 4.2 to be paid no later than 30 days from receipt of the invoice. Failure to pay USL in accordance with the terms of the invoice shall constitute a breach of this Option Agreement. | cmp |
On September 29, 2021, all of the above parties entered into a Separation and Settlement Agreement (Separation and Settlement Agreement), effective October 1, 2021, and terminated their mutual obligations under the Option Agreement and Improvement Loan Agreement. Pursuant to the Separation and Settlement Agreement, with respect to the: | cmp |
(e) Nothing contained in Article III, any Option Agreement or in any other agreement executed in connection with the granting of an Option under this Article III will confer upon any Optionee any right with respect to the continuation of his or her status as an employee or director of the Company or any of its Subsidiaries. | cmp |
(o) "HIGH MARSH OPTION" means the option granted to Aurora Gold Corporation by High Marsh pursuant to that certain mineral property option agreement entered into between Aurora Gold Corporation and High Marsh dated January 20, 2000, as amended by letter agreement dated June 19, 2000 and further amended by agreements made as of and effective July 28, 2000 and January 25, 2001, a copy of which, as amended, is attached hereto as Schedule "D", and transferred to the Company by Aurora Gold Corporation by transfer agreement dated May 18, 2000 between Aurora Gold Corporation and the Company, a copy of which is attached hereto as Schedule "E"; (p) "INDEMNIFYING PARTY" and "INDEMNIFIED PARTY" shall have the meanings ascribed to them, respectively, in Section 5.5 hereof; | cmp |
4.1 Additional Services; Disposal of Injectable Saltwater. Pursuant to this Option Agreement, USL will perform standard off-loading and customary handling services associated with disposal of NOW up to, and including, the Annual Volume at no additional charge. USL will perform additional services upon request of NESI at the market rates of USL for such services, or at such other rates as the parties may mutually agree upon. All charges for such additional services shall be in addition to and independent of the Option Payment. USL will accept injectable saltwater at the Landfarms for disposal upon request of NESI at the market rates of USL for disposal of injectable saltwater, or at such other rates as the parties may mutually agree upon. All charges for disposal of injectable saltwater shall be in addition to and independent of the Option Payment. | cmp |
On December 23, 1998, the Registrant entered into a real estate purchase agreement ("Purchase Agreement") by and among the Registrant, Salvatore Crimi and Sun Associates, LLC ("Sun Associates"), a limited liability company controlled by Betty Sun, (as record title holder) who is the wife of Pershing Sun, a director of the Registrant. Pursuant to the terms of the Purchase Agreement, the Registrant and Salvatore Crimi agreed to sell to Sun Associates certain property located in Hauppauge New York which is improved with the Registrant's executive offices containing approximately 12,000 square feet of space and a surface parking lot (the "Property"). The purchase price for the Property was $1,100,000. Mr. Crimi was not personally entitled to any portion of the proceeds for the sale of the Property and was only involved in the transaction to the extent that certain title issues required his involvement. Of the proceeds received by the Registrant $782,325.74 was used to pay the mortgage securing the Property. The balance of the proceeds was used for working capital by the Registrant. Simultaneously with the sale of the Property, the Registrant and Sun Associates entered into a lease agreement (the "Lease Agreement") pursuant to which Sun Associates leased the Property to the Registrant. Under the lease agreement, the annual basic rent for the Property during the period commencing December 31, 1998 and ending on December 31, 1999 is $168,000. Such annual basic rent increases, by an amount not greater than $8,985 during each year of the term of the Lease Agreement. As part of the Lease Agreement, the Registrant and Sun Associates entered into a repurchase option agreement (the "Option Agreement") which provides that the Registrant may repurchase the property at any time prior to June 23, 1999 at a purchase price of $1,155,000, net of Sun Associates' transaction costs, provided that the Registrant is not in default under the Lease Agreement. The Lease Agreement further provides that if Sun Associates sells the Property prior to the December 31, 1999 then 50% of the profits resulting from the sale will be paid to the Registrant provided that the Registrant is not in default under the Lease Agreement. | cmp |
(m) "Option Agreement" shall mean the written agreement described in ---------------- Section 6(c) evidencing the grant of an Option to a Nonemployee Director and containing the terms, conditions and restrictions pertaining to such Option. "Written agreement" shall include electronic acceptance of an electronic form of agreement. | cmp |
On December 23, 1998, the Registrant entered into a real estate purchase agreement ("Purchase Agreement") by and among the Registrant, Salvatore Crimi and Sun Associates, LLC ("Sun Associates"), a limited liability company controlled by Betty Sun, (as record title holder) who is the wife of Perishing Sun a director of the Registrant. Pursuant to the terms of the Purchase Agreement, the Registrant and Salvatore Crimi agreed to sell to Sun Associates certain property located in Hauppauge New York which is improved with the Registrant's executive offices containing approximately 12,000 square feet of space and a surface parking lot (the "Property"). The purchase price for the Property was $1,100,000. Mr. Crimi was not personally entitled to any portion of the proceeds for the sale of the Property and was only involved in the transaction to the extent that certain title issues required his involvement. Of the proceeds received by the Registrant $782,325.74 was used to pay the mortgage securing the Property. The balance of the proceeds was used for working capital by the Registrant. Simultaneously with the sale of the Property, the Registrant and Sun Associates entered into a lease agreement (the "Lease Agreement") pursuant to which Sun Associates leased the property to the Registrant. Under the lease agreement, the annual basic rent for the Property during the period commencing December 31, 1998 and ending on December 31, 1999 is $168,000. Such annual basic rent increases, by an amount not greater than $8,985 during each year of the term of the Lease Agreement. As part of the Lease Agreement, the Registrant and Sun Associates entered into a repurchase option agreement (the "Option Agreement") which provides that the Registrant may repurchase the property at any time prior to June 23, 1999 at a purchase price of $1,155,000, net of Sun Associates' transaction costs, provided that the Registrant is not in default under the Lease Agreement. The Lease Agreement further provides that if Sun Associates sells the Property prior to the December 31, 1999 then 50% of the profits resulting from the sale will be paid to the Registrant provided that the Registrant is not in default under the Lease Agreement. | cmp |
The granting of an option shall take place at the time specified by the Committee. Only if expressly so provided by the Committee shall the granting of an option be regarded as taking place at the time when a written option agreement shall have been duly executed and delivered by or on behalf of the Company and the Optionee to whom such option shall be granted. The agreement shall provide, among other things, that it does not confer upon an Optionee any right to continue in the employ of the Company and/or one or more of its subsidiaries or to continue as a director or consultant of the Company, and that it does not interfere in any way with the right of the Company or any such subsidiary to terminate the employment of the Optionee at any time if the Optionee is an employee, to remove the Optionee as a director of the Company if the Optionee is a director, or to terminate the services of the Optionee if the Optionee is a consultant. | cmp |
10.1 Lake Owen Option Agreement, dated July 27, 1999, by and between General Minerals Corporation and the Company. (5) 10.2 Stock Purchase Agreement, dated as of December 29, 1999, between Tigris Financial Group Ltd. and the Company. (5) | cmp |
11. Governing Law. The operation of, and the rights of Non-Employee Directors under, the Plan, the Option Agreements, and any Options granted hereunder shall be governed by the laws of the Commonwealth of Pennsylvania. | cmp |
(1) Granted to Jerald L. Kent pursuant to his employment agreement and related option agreement. | cmp |
13. OPTION AGREEMENT means an agreement between the Company and a Participant executed and delivered pursuant to the Plan. | cmp |
g. In the event of any Termination pursuant to Section 5, the Executive shall be entitled to retain (i) any and all options to purchase capital stock of the Company granted to the Executive pursuant to the terms and conditions of the Option Agreement attached as Exhibit "A" hereto that have vested as of the date of such Termination. | cmp |
8.3 Services and Equipment. USL possesses the business, professional and technical expertise to handle, treat and dispose of NOW and possesses the equipment, plant and employee resources required to perform this Option Agreement. USL shall use its commercially reasonable efforts to turn all barges delivering materials to the Landfarms in a timely manner consistent with the number of NESI and third-party generator barges on site at such moment and with its general practice of giving priority to third-party generators' barges. The equipment shall, at all times relevant to the performance of services hereunder, be maintained in good and safe condition and fit for use. | cmp |
10.26 Amendment to United Meridian Corporation 1994 Non-Qualified Stock Option Agreement for Former Employees of General Atlantic Resources, Inc. dated as of April 16, 1996 among UMC and Donald D. Wolf, incorporated by reference to Exhibit 10.22 to the Company's Form 10-Q for the period ended June 30, 1996 filed with the Securities and Exchange Commission on August 8, 1996. | cmp |
7.3 LLC Interests Subject to Option Rights. If any LLC Interests purchased by Wilmington pursuant to Sections 7.2 or 7.3 are subject to the rights of an individual who has been granted the option to purchase such LLC Interests pursuant to an Option Agreement, that option holder shall retain all rights granted by that Option Agreement. | cmp |
A. interpret the provisions of the Plan or of any Option or Option Agreement and to make all rules and determinations which it deems necessary or advisable for the administration of the Plan; B. determine which employees of the Company or of an Affiliate shall be designated as Key Employees and which of the Key Employees shall be granted Options; | cmp |
5.1 Performance of Option Agreement. Newpark hereby covenants and agrees that it shall cause NESI to fully perform all of its obligations under this Option Agreement in a timely manner. Newpark further covenants and agrees that it shall take all action, including, without limitation, supplying information necessary for the determination of quantities of NOW that may be delivered pursuant to this Option Agreement, or shall refrain from taking any action, as is necessary or appropriate, to permit NESI to fully perform all of its obligations under this Option Agreement in a timely manner. | cmp |
6.5 Inspection and Testing of Material. After all inspections, if any, pursuant to Section 6.4 have been concluded, USL shall conduct inspections, testing and sampling using such equipment and procedures as are required by or consistent with its permits. USL may rely exclusively on the results of its inspection in determining whether materials delivered may be disposed at the Landfarm in accordance with its permits and this Option Agreement. NESI authorizes USL to retain samples and all data relating thereto, including test results, for so long as required by federal, state or local law, ordinance, permit, regulation, directive, code, standard or requirement and additionally for so long as USL in its sole discretion shall determine. | cmp |
(b) Property Option Agreements. | cmp |
January 6, 2005 Filing of finder's fee agreement with The Shemano Group, Inc., option agreement with Beth Broday, and certificate of designations for Convertible Preferred Stock; announcement of completion of January 2005 private placement Series C Preferred Stock and warrants for $15 million; filing of documents related to January 2005 private placement. | cmp |
We agreed to purchase an option to purchase the Pinguino property in a mineral property option agreement dated February 24, 2004 between our company and Christopher Dyakowski, who became our President, Secretary, Treasurer and a member of our board of directors immediately after this transaction was completed. The purchase price for the option was approximately $393,500 (CAD $450,000) and was paid in five installments as follows: * approximately $43,710 (CAD $50,000), paid on July 1, 2004;
* approximately $65,565 (CAD $75,000), paid on September 9, 2005;
* approximately $87,420 (CAD $100,000), paid on July 1, 2006;
* approximately $87,420 (CAD $100,000), paid on June 26, 2007; and
* approximately $109,275 (CAD $125,000) paid on June 5, 2008. | cmp |
In 1998, the Company intends to further develop the Ryan Lode property under the terms of its option agreement with La Teko. The purpose of this work would be to determine whether a feasibility study, suitable for institutional financing, could be prepared so as to finance the capital costs associated with returning the Ryan Lode to commercial production. The Company also intends to resume development of its Nolan claims, subject to available financing. | cmp |
(a) Option Agreement Figlenski/Carlson/Silverado (6/9/81) is incorporated by reference to Exhibit 0(e)(vi)(a) to Silverado's Registration Statement on Form 10, No. 0-12132, filed May 11, 1984, as amended on Form 8, filed July 10, 1984. | cmp |
(a) 10.33 Option Agreement, dated as of July 2, 1975, among Litton Industries, Inc. and Litton Industries
Leasing Corporation and United States Steel Corporation. | cmp |
MASTER LEASE AND OPTION AGREEMENT | cmp |
In February 2017, we entered into a master biomass purchase and sale agreement and a confirmation thereunder with the sponsor (together, the Option Contract), pursuant to which we have the option to purchase certain volumes of wood pellets from the sponsor and the sponsor has a corresponding right to re-purchase volumes purchased by us. The Option Contract terminated in accordance with its terms in March 2018. | cmp |
10.39 Option Agreement, dated as of May 19, 2003, Exhibit 10.2 to Form 8-K filed January 6, 2005
between SLS International, Inc. and Beth Broday 10.40 Securities Purchase Agreement, dated January 3, Exhibit 10.3 to Form 8-K filed January 6, 2005
2005, among SLS International, Inc., Baystar
Capital II, L.P., PSO Trading IV, LLC, HFTP
Investment L.L.C., and Royal Bank of Canada | cmp |
Option Agreement, dated June 2, 2004, between SLS Exhibit 10.2 to Form 10-QSB filed August 13, 2004
International, Inc. and Global Drumz, Inc. | cmp |
Wilmington also entered into a throughput option agreement with our sponsor granting the sponsor, subject to certain conditions, the option to obtain terminal services at the Wilmington terminal at marginal cost throughput rates for wood pellets produced by one of our sponsors potential wood pellet production plants. | cmp |
Biomass Option Agreement Enviva Holdings, LP | cmp |
In February 2017, Enviva, LP entered into an agreement and a confirmation thereunder with the sponsor (together, as amended, the Option Contract), pursuant to which Enviva, LP had the option to purchase certain volumes of wood pellets from the sponsor and the sponsor had a corresponding right to re-purchase volumes purchased by Enviva, LP. | cmp |
Option Agreement, dated as of May 19, 2003, between SLS Exhibit 10.2 to Form 8-K filed January 6, 2005
International, Inc. and Beth Broday Securities Purchase Agreement, dated January 3, 2005, among Exhibit 10.3 to Form 8-K filed January 6, 2005
SLS International, Inc., Baystar Capital II, L.P., PSO
Trading IV, LLC, HFTP Investment L.L.C., and Royal Bank of
Canada | cmp |
6.2 Legal Fees. The Company agrees to pay any and all reasonable legal fees and other expenses that may be incurred by Vitelle in connection with his efforts to seek a resolution of any dispute with the Company arising under this Agreement or the Option Agreements, but only if Vitelle shall have obtained a judgment in his favor against the Company. | cmp |
8.5 Entire Agreement. This Agreement supersedes any and all prior written or oral agreements between Vitelle and the Company and, together with the Option Agreements, evidences the entire understanding of the parties hereto with respect to the terms and conditions of Vitelle's employment with the Company. | cmp |
In September 2016, the Company entered into a license and option agreement with Janssen (the License and Option Agreement) under which Janssen granted the Company a license to technology and intellectual property to develop, manufacture and commercialize two compounds: a small molecule inhibitor of androgen receptor and androgen receptor mutations (the AR Mutant Program or TRC 253), which is intended for the treatment of men with prostate cancer, and an inhibitor of NF-k B inducing kinase (the NIK Program or TRC 694). Following completion of the pre-clinical development of TRC 694, the Company determined the compound did not warrant further development and, in February 2019, issued written notice to terminate the License and Option Agreement with respect to the NIK Program and returned TRC 694 and all rights thereto to Janssen. | cmp |
Adare Development and Option Agreement | cmp |
In March 2018, the Company entered into an exclusive development and option agreement with Adare Pharmaceuticals (formerly known as Orbis Biosciences, and which the Company refers to as Adare), for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (ORB-204 and ORB-214, respectively). Under this agreement, the Company paid Adare $300,000 to conduct the first stage of development work, Stage 1, as follows: $150,000 upon signing the agreement, $75,000 at the 50% completion point, not later than 6 months following the date the agreement was signed (which the Company paid in September 2018), and $75,000 upon delivery by Adare of the 6-month batch, not later than 11 months following the date the agreement was signed (which the Company paid in January 2019). | cmp |
(t) "Option Agreement" means an agreement between the Company and an Optionee evidencing the terms and conditions of an individual Option grant. The Option Agreement is subject to the terms and conditions of the Plan. | cmp |
Subsets and Splits
CMP Labels with Stock or Employee
Retrieves rows where the label is 'cmp' and the text mentions 'stock' or 'employee', providing a basic filtered view of the data.
Select Law Labels
Returns all entries from the train dataset labeled as 'law', providing a basic filter without much analytical insight.
Select Text and Label
The query retrieves text and label pairs from the train dataset, providing a basic view of the data without much analytical insight.